Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | DRD5 | P21918 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 11/20 | 0.53 |
| ▸ | HTR7 | P34969 | 9/20 | 0.53 |
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | HTR6 | P50406 | 8/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL6999262 | 0.93 | DRD2 (0.51) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6995806 | 0.92 | DRD2 (0.45) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6995999 | 0.92 | DRD2 (0.45) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6987484 | 0.91 | DRD2 (0.56) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6998179 | 0.90 | DRD2 (0.47) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6998557 | 0.87 | ADRB2 (0.42) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6994468 | 0.87 | DRD2 (0.41) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6996875 | 0.87 | CACNA1G (0.41) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6991302 | 0.86 | TDP1 (0.42) | DRD2DRD3DRD5DRD4HTR1A | |
| Ethylene SCHEMBL6996278 | 0.86 | HTR1A (0.46) | DRD2DRD3DRD5DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | DRD2 402/4885DRD3 341/4885DRD5 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.